MSB Trading 2020 - a new dawn, page-8487

I am guessing the MSB scientist will be able to tell which patient had Rem-L v placebo (i.e. if they're studying biomarkers in the blood, they will know from these markers which patient had Rem-L vs placebo?).

Another company doing P3 trials was able to give almost weekly updates as they laced their drug with an ingredient that made the blood glow so they could easily tell which patient had their drug or placebo - so perhaps it is not as easy on a quick view, but surely when you analyse the bloods you will be able to determine.

Will be interesting to know, as if MSB management can work out who got Rem-L v placebo (therefore may be able to rudimentary work out how many deaths have occurred in placebo arm v treatment arm), it may go towards the reason as to why they have been so confident in getting approval for Rem-L, and why they have 10,000 doses ready - plus, why they may be content to not do anymore aGHVD trials if they believe COVID will be approved.